Kexing Biopharm Co., Ltd. (688136.SH) announced that on November 6, 2025, it submitted an application to The Stock Exchange of Hong Kong Limited (HKEX) for the issuance of H-shares and listing on the Main Board of HKEX. On the same day, the company published the application materials on HKEX's website.
The materials were prepared and disclosed in compliance with the requirements of the Securities and Futures Commission of Hong Kong (SFC) and HKEX. As a draft version, the information contained may be updated or revised from time to time. Investors are advised not to make any investment decisions based solely on these materials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments